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In September 2012, the United Stated Food and Drug
Administration approved the use of a fully subcutaneous
implantable cardiac deﬁbrillator (S-ICD, Boston Scientiﬁc
Inc). The device is implanted in the left midaxillary space
and attached to a single lead that is tunneled subcuta-
neously from the xyphoid process in 2 directions, superi-
orly to the sternal manubrium joint to the left of the
sternum and laterally to the pulse generator. The lead
consists of a single coil in the portion of lead along the
sternum and 2 sensing electrodes, 1 at the tip of the lead at
the upper portion of the sternum and 1 at the xyphoid
process. Sensing is achieved via 1 of 3 potential conﬁg-
urations: between the device and the lower electrode,
between the device and the upper electrode, or between the
3 electrodes. The sensing vector is automatically chosen
by the device to minimize the chance of T-wave over-
sensing, but it can be manually overriden.1
A deep brain stimulator (DBS) is an electronic device
consisting of a pulse generator and 1 or more electrodes
implanted in the brain. It can be programmed to operate in a
bipolar or unipolar stimulation mode. It is used for the
treatment of Parkinson disease, among other neurologic
conditions.2 Manufacturer’s recommendations for concom-
itant use of a transvenous implantable cardiac deﬁbrillator
(ICD) and DBS include setting the ICD to bipolar sensing.
Sensing in an S-ICD is achieved via much wider bipoles than
in a transvenous ICD, raising the concern of adverse
interaction between the 2 devices. To our knowledge, weKEYWORDS Subcutaneous deﬁbrillator; Deep brain stimulator; Deﬁbrillation
threshold testing; Implantable cardiac deﬁbrillator; Cardiac device
interaction
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).present the ﬁrst case report of successful implantation of an
S-ICD in a patient with a previously implanted DBS.Case report
A 51-year-old man presented as an outpatient to our
institution for consideration of an S-ICD implantation. His
past medical history consisted of coronary artery disease, for
which he had undergone placement of multiple coronary
stents, and early-onset Parkinson disease, for which he had
undergone implantation of a Medtronic Activa DBS in the
right prepectoral area. In 1996, he had an episode of
polymorphic ventricular tachycardia, which resulted in
cardiac arrest. At that time, a single-chamber ICD was
implanted in the left prepectoral area for secondary preven-
tion of sudden cardiac death. His left ventricular ejection
fraction was and remains normal. Between 1996 and 2005,
he underwent 4 ICD generator replacements. His initial right
ventricular lead was a Ventritex Cadence single-coil lead,
which failed and was replaced by a dual-coil St. Jude
Medical Riata lead in 2005. In view of the recent Food and
Drug Administration recommendation,3 the patient under-
went routine surveillance imaging of the lead at another
institution and was found to have externalization of a
conductor on ﬂuoroscopy. In addition, an acute rise in the
right ventricular threshold from 1 to 3.5 V was noted.
Because of a lack of conﬁdence in the reliability of the
Riata lead and the patient’s desire to continue to have
protection from sudden cardiac death, the patient was given
multiple options, including extraction of the transvenous
lead and implantation of new transvenous lead, or abandon-
ment of the leads and implantation of an S-ICD. The
decision-making was complicated by the presence of the
Medtronic Activa DBS, which had provided him with
signiﬁcant relief from parkinsonian symptoms.
In patients with Parkinson disease, the DBS works by
bilateral stimulation of the internal globus pallidus or the
subthalamic nucleus. Our patient had a single unit with 2
leads, 1 to each cerebral hemisphere. Each lead has 4
electrodes, and the device can be programmed to stimulate
in either a unipolar or bipolar fashion. The device can bepen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 The subcutaneous cardiac deﬁbrillator (S-ICD)
represents a major advance in ICD technology with the
ability to provide sudden death prevention without
transvenous leads. Because of its wide sensing bipole,
interaction with other implanted electronic devices is
a concern. This includes patients with a deep brain
stimulator (DBS), which is used for treatment of
neurologic disorders such as Parkinson disease.
 Implantation of an S-ICD in patients with a
preexisting DBS requires a multidisciplinary
approach with the patient’s neurologist for
programming the DBS to a bipolar mode if possible
to limit the possibility of interaction with the S-
ICD. In addition, technical support should be
available during S-ICD implantation to test sensing
with different DBS settings and for interrogation of
the DBS after deﬁbrillation threshold testing.
 This case report outlines an approach that was
successful when both devices coexisted in the same
patient without any adverse effect on the S-ICD or
the patient’s neurologic symptoms.
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deliver 2 to 250 Hz at a pulse width of 60 to 450 μs and up
10.5 V (voltage mode) or 25.5 mA (current mode).
The patient’s DBS had been chronically programmed to
unipolar stimulation between the DBS pulse generator and the
lead(s). As a ﬁrst step to facilitate S-ICD implantation, weFigure 1 Surface ECG tracing showing transition of DBS stimulation from uni
clearly appreciated in the ﬁrst third of the tracing. DBS ¼ deep brain stimulator.requested that the DBS be changed to a bipolar mode. Symptom
relief from parkinsonian symptoms persisted in bipolar mode.
The 2 DBS leads in the patient’s DBS can be programmed
independently. The left hemisphere lead was programmed to
an output of 3.V, and the right hemisphere lead was
programmed to 2.1 V. The pulse width and frequency of
both leads were the same at 90 μs and 180 Hz, respectively.
During implantation of the S-ICD and deﬁbrillation thresh-
old (DFT) testing, these settings were not manipulated.
Avoidance of T-wave oversensing by an S-ICD requires
screening surface ECG recordings simulating the sensing
vectors of the S-ICD. Application of a template provided by
the manufacturer determines eligibility, which was adequate
in this patient.
The patient was taken to the electrophysiology laboratory
for implantation of the S-ICD. A programmer and a techni-
cian were available to alter the programming of the DBS as
needed. The procedure was performed with the patient under
general anesthesia. The S-ICD implantation technique has
been described elsewhere.4 We performed the standard
technique with a modiﬁcation: we used a sheath in con-
junction with the tunneling tool to place the lead along the left
side of the sternum, which avoids the superior third incision.
After implantation, we tested for interaction of the S-ICD
and the DBS. Changing between unipolar and bipolar
stimulation on the DBS was immediately apparent on the
surface ECG (Figure 1).
The S-ICD sensing vectors were recorded with the DBS in
both unipolar and bipolar conﬁgurations. There was no
oversensing of DBS activity (in both bipolar and unipolar
modes) by the S-ICD (Figure 2). DFT testing was performed
with successful sensing and termination of induced ventricular
ﬁbrillation at 65, 50, and 35 J. The DBS was active in bipolarpolar to bipolar mode. The artifact created by the DBS in unipolar mode is
Figure 2 Representative example of subcutaneous implantable cardiac deﬁbrillator (S-ICD) recording during unipolar stimulation. One representative tracing
is shown. There was no S-ICD oversensing in both DBS unipolar and bipolar modes in all S-ICD sensing vectors.
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testing and found no interruption in normal function.
On routine follow-up 12 months after implantation, the
patient was doing well with no complications. He had not
received any S-ICD shocks. Chest x-ray ﬁlm showed a well-
positioned S-ICD device and electrode (Figure 3).Discussion
DBS is an increasingly common treatment for a variety of
neurologic disorders, including Parkinson disease, so the
possibility of a patient requiring both an ICD and a DBS is
increasing. Three previous case reports have documented the
safety and lack of interaction between transvenous ICDs and
DBS. However, 1 case report did document resetting of a
DBS to an off mode after DFT testing of a transvenous ICD.5
To our knowledge, this is the ﬁrst report of the safe
implantation and follow-up of an S-ICD with a DBS. There
was no issue acutely with interaction of the DBS and ICD with
the DBS in either bipolar or unipolar mode, and in all 3 sensing
vectors of the S-ICD. The lack of DBS artifact on the S-ICD
(even with unipolar DBS stimulation) likely is due to signal
ﬁltering in the S-ICD. The DBS was programmed to a
stimulation frequency of 180 Hz both chronically and duringFigure 3 Posteroanterior chest C-ray ﬁlm after subcutaneous implantable
cardiac deﬁbrillator (S-ICD) implantation. DBS ¼ deep brain stimulator.the implantation. The S-ICD allows frequencies between only 3
and 40 Hz to pass and thus eliminates the DBS signal. In
contrast, the recording system in the electrophysiology labo-
ratory where the case was performed allows frequencies of 30
to 250 Hz to pass, making DBS unipolar stimulation apparent
on the surface ECG. Bipolar DBS stimulation was not seen on
the ECG recording, probably because it was of much lower
amplitude than unipolar stimulation. Sensing of ventricular
ﬁbrillation by the S-ICD was unaffected by active bipolar
stimulation from the DBS. In addition, the 3 ICD shocks
delivered for DFT testing did not adversely affect the DBS.
It is important to note that, during follow-up, the DBS was
left in bipolar mode and the S-ICD remained in its automati-
cally selected ideal sensing vector. It is not clear from this
report whether with the DBS in unipolar mode or a different
S-ICD sensing vector and the DBS in either mode that
oversensing and interaction may not have occurred during
follow-up. DBS devices can also be programmed to fre-
quencies that are well within the ﬁlter pass range of the
S-ICD, which may result in a higher risk of interaction. In
addition, it is not clear whether S-ICD sensing chronically or
DBS function after an S-ICD shock would be unaffected if
the DBS were on the left side of the patient.
An additional issue that may arise with the combination of
these 2 devices is the manner in which the DBS behaves after a
power on reset event, which theoretically can occur after an ICD
shock. The current generation of Medtronic devices, 1 of which
was present in this patient, resets to the previously programmed
parameters, even after multiple resets. However, older gener-
ations of DBS devices (which still are available but infrequently
used) will revert to the default settings, which vary, but do
include, in some instances, a stimulation frequency of 30 Hz,
which is within the pass ﬁlters limits of the S-ICD and would
increase the risk of oversensing of DBS stimulation by the ICD.
For patients with an S-ICD, such older-generation DBS devices
probably should be avoided. For patients with preexisting older-
generation DBS, this issue should be taken into account when
considering a new S-ICD implantation.
Given the inherent limitations of a single case report, caution
should be exercised in applying these ﬁndings to similar clinical
situations. Ideally, a series of such cases would be useful to
better understand the potential interactions and issues that may
arise when these devices coexist in a single patient.
Heart Rhythm Case Reports, Vol 1, No 4, July 2015244References
1. Majithia A, Estes NAM, Weinstock J. Advances in sudden death prevention:
the emerging role of a fully subcutaneous deﬁbrillator. Am J Med 2014;127:
188–194.
2. Miocinovic S, Somayajula S, Chitnis S, Vitek JL. History, applications, and
mechanisms of deep brain stimulation. JAMA Neurol 2013;70:163–171.3. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm314930.htm.
Accessed 4/22/2015.
4. Rowley CP, Gold MR. Subcutaneous implantable cardioverter deﬁbrillator. Circ
Arrhythm Electrophysiol 2012;5:587–593.
5. Ooi YC, Falowski S, Wang D, Jallo J, Ho RT, Sharan A. Simultaneous use of
neurostimulators in patients with a preexisting cardiovascular implantable elec-
tronic device. Neuromodulation 2011;14:20–25, discussion 25–26.
